Montelukast in Hospitalized Patients Diagnosed with COVID-19

Ahsan Khan

Rutgers Cancer Institute of New Jersey

Christian Misdary

Rutgers Cancer Institute of New Jersey

Nikhil Yegya-Raman

University of Pennsylvania

Sinae Kim

Rutgers Cancer Institute of New Jersey

Navaneeth Narayanan

Rutgers University Ernest Mario School of Pharmacy

Sheraz Siddiqui

Rutgers Robert Wood Johnson Medical School

Padmini Salgame

The Center for Emerging Pathogens, Department of Medicine, Rutgers University

Jared Radbel

Rutgers Robert Wood Johnson Medical School

Frank De Groote

Medical Sante, Sint-Kruis, Brussels

Carl Michel

Rutgers Cancer Institute of New Jersey

Janice Mehnert

NYU Langone Health

Caleb Hernandez

Coney Island Hospital, Department of Emergency Medicine

Thomas Braciale

University of Virginia Medical Center, Carter Immunology Center

Jyoti Malhotra

Rutgers Cancer Institute of New Jersey

Michael A. Gentile

Merck & Co Inc

Salma K. Jabbour (✉ jabbousk@cinj.rutgers.edu)

Rutgers Cancer Institute of New Jersey

Research

Keywords: COVID-19, Viral Infection, Hypoxemia

Posted Date: August 5th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-52430/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Journal of Asthma on March 4th, 2021. See the published version at <https://doi.org/10.1080/02770903.2021.1881967>.

Abstract

Background Several therapeutic agents have been assessed for the treatment of COVID-19, but few approaches have been proven efficacious. Because leukotriene receptor antagonists such as montelukast have been shown to reduce both cytokine release and lung inflammation in preclinical models of viral influenza and acute respiratory distress syndrome, we hypothesized that therapy with montelukast would reduce clinical deterioration as measured by the COVID-19 Ordinal Scale.

Methods We performed a retrospective analysis of COVID-19 confirmed hospitalized patients treated with or without montelukast. We used “clinical deterioration” as the primary endpoint, a binary outcome defined as any increase in the Ordinal Scale value from Day 1 to Day 3 of hospital stay, as these data were uniformly available for all admitted patients before hospital discharge. Rates of clinical deterioration between the montelukast and non-montelukast groups were compared using the Fisher’s exact test. Univariate logistic regression was also used to assess the association between montelukast use and clinical deterioration.

Results A total of 92 patients were analyzed, 30 received montelukast at the discretion of the treating physician and 62 patients who did not receive montelukast. Patients receiving montelukast experienced significantly fewer events of clinical deterioration compared to patients not receiving montelukast (10% vs 32%, $p = 0.022$). Sensitivity analysis among those without asthma showed a trend toward fewer clinical deterioration events in the montelukast group than non-montelukast groups (11% vs 33%, $p = 0.077$). Sensitivity analysis among those who did not receive azithromycin showed fewer clinical deterioration events in the montelukast group vs. non-montelukast groups (8% vs 32%, $p = 0.030$).

Conclusions Our findings suggest that montelukast associates with a reduction in clinical deterioration for COVID-19 confirmed patients as measured on the COVID-19 Ordinal Scale. Montelukast may have activity in COVID-19 infection, and future efforts should evaluate this potential therapy.

Background

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been the focal point of the global community since its outbreak in December 2019 due to its tremendous impact on international health, mortality, and the economy. Following the release of conflicting reports of the efficacy of hydroxychloroquine and the expedited clinical trial evaluation of remdesivir, the biomedical community has struggled to find sufficient, effective therapeutic regimens to manage patients with COVID-19 infection¹. The clinical spectrum of COVID-19 ranges from mild, self-limiting respiratory tract illness to severe progressive pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, and death². In a series outlining the clinical characteristics of hospitalized COVID-19 confirmed patients, common symptoms included fever (88.7%), cough (67.8%), fatigue (38.1%), sputum production (33.7%) and shortness of breath (18.7%)². To date, there are no accepted guidelines

for the supportive care of COVID-19 patients and the effective management of symptoms, and stop gap therapies represent an unmet need.

There is increasing evidence that the severity of COVID-19 infection is modulated by excessive inflammation, as there are increased levels of interleukin-6 (IL-6), C-Reactive Protein (CRP) procalcitonin, interleukin-2 (IL-2), interleukin-10 (IL-10), and tumor necrosis factor alpha (TNF- α) observed in patients who undergo hospitalization³. Moreover, patients with severe disease develop the potentially lethal inflammatory complications of cytokine release syndrome and ARDS⁴. In addition, SARS-CoV-2 directly infects alveolar cells, further limiting gas exchange within the lung⁵.

In a murine model of influenza infection, alveolar injury and compromised respiratory function, leading to ARDS was mediated by leukotriene receptor signaling in Type-1 Alveolar Epithelial Cells (T1AECs)⁶. In this preclinical study by Braciale et al., leukotriene receptor antagonists (LTRAs) prevented the development of fatal influenza pneumonia in mice with influenza infection⁶. LTRAs prevented the uptake of influenza virus by the terminal airway alveolar cells and infection of these cells, involved in oxygen exchange⁶. This infection in the lungs manifested as diffuse alveolar damage leading to ARDS⁶. Therefore, it appears that virally mediated lung injury from SARS-CoV-2 and influenza may precipitate similar molecular mechanisms in the lung parenchyma resulting in ARDS.

LTRAs, including montelukast, are used to treat seasonal allergic rhinitis and asthma, and evidence suggests that its administration can be used in other upper airway inflammatory diseases⁷. Mullol et al. explored montelukast's anti-inflammatory properties in an in vitro model of upper eosinophil inflammation and found that montelukast had a significant inhibitory effect on the production GM-CSF, IL-6 and IL-8⁸. These anti-inflammatory effects on epithelial cell cytokine secretion and on eosinophil survival suggest that montelukast may contribute to the reduction of eosinophilic inflammation in upper-airway inflammatory diseases. Also, in an additional mouse model of ARDS, montelukast decreased the release of pro-inflammatory cytokines implicated in severe COVID-19 (IL-6 and TNF- α)⁹. In sum, these data suggest that LTRAs such as montelukast can may prevent progression to severe lung disease associated with COVID-19. Accordingly, clinicians reported that montelukast helps hospitalized patients with COVID-19 recover sooner and/or reverses respiratory decline¹⁰. Montelukast therapy reduces the number of pro-inflammatory cytokines, and thus, may serve as a potential treatment for COVID-19¹.

We examined the impact of montelukast administration in confirmed COVID-19 positive patients who were hospitalized based on the understanding that montelukast can reduce inflammatory markers contributing to improved pulmonary function. We hypothesized that montelukast administration in hospitalized patients with confirmed COVID-10 infection would reduce clinical deterioration, as measured by the COVID-19 Ordinal Scale¹¹.

Methods

We conducted a retrospective, IRB-approved, study at Robert Wood Johnson University Hospital, Rutgers University (Pro2020001307) in New Brunswick, New Jersey. From late March to early April 2020, upon admission, at the discretion of the treating provider, patients received montelukast. We identified a group of 30 patients who received montelukast and 62 non-montelukast (control) patients. The patients who received montelukast were started on 10 mg/day on Day 1 of admission. The control group of patients were selected consecutively from a hospital database listing confirmed COVID-19 patients who survived to at least the fourth day of admission.

From March 19- March 27, 2020, the standard treatment for patients hospitalized at Robert Wood Johnson University Hospital with confirmed COVID-19 consisted of hydroxychloroquine 400 mg BID for 5 days and azithromycin. After this time, this institutional guideline changed and many patients received a course of azithromycin for co-infection coverage at the discretion of the treating physician. Data collected included patient demographics, medical history, vital signs including pulse oximetry, laboratory test results, medication administration, supplemental oxygen usage, physician assessments and radiology reports. Based on the objectivity of assessing supplemental oxygen use, these data were the focus of this study. Specifically, we employed the COVID-19 Ordinal Scale, which allowed for categorization of oxygen escalation through a widely accepted, standardized scale (Table 1)¹¹. For the purposes of this study, patients were included only if found to have an Ordinal Scale score of 3 or higher indicating the need for hospitalization at the time of their assessment. When analyzing Ordinal Scale scores, laboratory results, and vital signs in both the montelukast and non-montelukast groups, a delta calculation was used between Day 1 and Day 3. Day 1 and Day 3 were chosen to be analyzed as it was the most consistent time point, given the variations in lengths of stay.

Table 1
Ordinal Scale for Clinical Improvement (WHO)11

Patient State	Descriptor	Score
Uninfected	No clinical or virologic evidence of infection	0
Ambulatory	No limitation of activities	1
	Limitation of activities	2
Hospitalized, Mild Disease	Hospitalized, no oxygen therapy	3
	Oxygen by mask or nasal prongs	4
Hospitalized, Severe Disease	Non-invasive ventilation or high flow oxygen	5
	Intubation and mechanical ventilation	6
	Ventilation + additional organ support – vasopressors, RRT, ECMO	7
	Death	8

Table 2. Baseline Demographics and Clinical Characteristics in Montelukast (N = 30) and Non-Montelukast Patients (N = 62)

	Montelukast (N = 30)	Non-Montelukast (N = 62)	p-value
Median Age (range)	67 (37–93)	59 (46–75)	0.011*
Male, n (%)	15 (50)	38 (61.3)	0.30
Race n, (%)			0.51
Asian	3 (10)	8 (12.9)	
Black	4 (13.3)	8 (12.9)	
Hispanic	7 (23.3)	24 (38.7)	
White	3 (10)	5 (8.1)	
Other	13 (43.3)	17 (27.4)	
Symptoms on Admission, n (%)			
Fever	23 (76.7)	52 (83.9)	
Cough	27 (86.7)	47 (75.8)	
Shortness of Breath	22 (73.3)	48 (77.4)	
Baseline Comorbidity, n (%)			

Patient State	Descriptor		Score
Cardiac Disorder	13 (43.3)	15 (24.2)	0.06
Diabetes	13 (43.3)	23 (37.1)	0.57
Hypertension	21 (70)	34 (54.8)	0.16
Hyperlipidemia	9 (30)	17 (27.4)	0.80
Cancer	2 (6.7)	3 (10)	0.66
Asthma	11 (36.7)	4 (6.5)	0.0005*
Steroid Use Between Day1 and Day 3 – Number Only, n (%)	5 (16.7)	14 (22.6)	0.51
Baseline Immunosuppression, n (%)	3 (10)	8 (12.9)	0.67
Medications During Hospital Stay, n (%)			
Anticoagulants	27 (90)	58 (93.5)	0.55
Statin or ARB	12 (40)	20 (46.8)	0.54
Glucocorticoids	10 (33.3)	25 (40.3)	0.52
Azithromycin	4 (13.3)	25 (40.3)	0.01*
Median Length of Hospitalization in days (IQR)	7 (4-10.5)	8(6–12)	0.26

Statistical Analysis:

We first assessed differences in baseline patient and treatment characteristics (Table 2) between the montelukast and non-montelukast groups. Association of categorical variables were assessed with the Fisher's exact test, as appropriate. Means of continuous variables were compared with an independent two-sample t-test or Wilcoxon rank-sum test, depending on normality of their distributions.

Additionally, we assessed the differences in Day 1 key laboratory values (white blood cell count, creatinine, lactic acid dehydrogenase (LDH), C-reactive protein (CRP), ferritin, and D-dimer) between groups, as well as differences in the change in laboratory values from Day 1 to Day 3, using the Wilcoxon rank-sum test and Wilcoxon signed-rank test, respectively.

We chose "clinical deterioration" as the primary endpoint, a binary outcome defined as any increase in the COVID-19 Ordinal Scale value from Day 1 to Day 3 of hospital stay, as these data were uniformly available for all admitted patients before discharge. Rates of clinical deterioration between the montelukast, and non-montelukast groups were compared using the Fisher exact test. Univariate logistic regression was also used to assess the association between montelukast use and clinical deterioration.

Multivariable logistic regression was also used to control for age, given the difference in age between groups. Because of the limited number of events, we only included a total of 2 variables in multivariable models (receipt of MTK and age). Odds ratio (OR) along with 95% confidence interval were estimated. To assess the potential confounding effect of other covariates on the primary outcome, we conducted three separate sensitivity analyses excluding patients with asthma, patients who received azithromycin and patients who received steroids (dexamethasone and prednisolone).

All statistical tests were 2-sided, and we considered $p < 0.05$ as statistically significant and $p < 0.10$ as a trend toward significance. We performed analyses using SAS version 9.4 (Cary, NC).

Results

Baseline characteristics

Table 2 demonstrates baseline patient and treatment characteristics in the montelukast and non-montelukast groups. Patients who received montelukast were older (median age, 67 years vs. 59 years, $p = 0.01$), had a greater proportion with asthma (36.7% vs. 6.5%, $p = 0.0005$), and received azithromycin at a lower rate (13% vs. 40%, $p = 0.009$). All patients were started on montelukast at the time of admission and did not have montelukast cited as an outpatient medication. There were no significant differences in other characteristics between groups, including Day 1 COVID-19 Ordinal Scale distribution ($p = 0.61$) or receipt of steroids between Days 1 and 3 of hospital stay (16.7% for montelukast group vs. 22.6% for non-montelukast group, $p = 0.51$).

Laboratory values

Baseline laboratory values (Table 4), as well as changes in laboratory values from Day 1 to Day 3, between groups were assessed (Table 5). Baseline LDH was lower in the montelukast group (median 344.5 vs. 439, $p = 0.04$). No other differences in baseline laboratory values were noted. There were no differences in the change in laboratory values (from Day 1 to Day 3) between groups.

Table 3
Delta Ordinal Scale and Overall Clinical Deterioration from Day to 1 Day 3 (N = 92)

Delta COVID-19 Ordinal Scale - Number (%)	Montelukast (N = 30)	Non-Montelukast (N = 62)	Total
-1	1 (0)	3 (6.3)	4
0	26 (84)	39 (66.7)	65
1	3 (12)	17 (20.8)	20
2	0 (0)	3 (6.3)	3
Total	30	62	92
Clinical Deterioration (Any Escalation in Ordinal Scale Value Day 1 to Day 3) - Number (%)	3 (10)	20 (32.2)	23

Table 4
Median Laboratory Values - Baseline

Laboratory Values - Median (Range)	Montelukast	Non-Montelukast	p-Value
WBC	7.2 (2.9–21.5)	7.55 (2.1–20.9)	0.68
D-Dimer	898.5 (359–11984)	888 (8.3–103565)	0.75
Ferritin	598.5 (80–5983)	937.5 (63–15708)	0.23
LDH	344.5 (153–625)	439 (156–1716)	0.04
CRP	10.72 (2.47–29.19)	12.8 (0.57–39.8)	0.14
Creatinine	0.9 (0.2–6.5)	0.9 (0.3–15.5)	0.85
Pulse Ox	93% (61% – 99%)	91% (57% – 100%)	

Table 5
Laboratory Values Delta Day 1 to Day 3

Laboratory Value - Delta Day 1 to Day 3	Montelukast	Non-Montelukast	p-Value
WBC	-0.4	-1	0.52
D-Dimer	-84.5	-54	0.62
Ferritin	55.5	41	0.78
LDH	3	-19	0.9
CRP	1.36	0.32	0.31
Creatinine	-0.1	-0.2	0.66
Pulse Ox	-1%	-1%	

Clinical deterioration

Table 3 shows specific changes in the Ordinal Scale value from Day 1 to Day 3 for the montelukast and no montelukast groups. Clinical deterioration (any escalation in Ordinal Scale value from Day 1 to Day 3) occurred in significantly fewer patients in the montelukast group (10% vs. 32.2%, $p = 0.022$). In univariate logistic regression, the montelukast group had a lower risk of clinical deterioration (odds ratio 0.23, $p = 0.029$, CI = 0.063–0.86). On multivariable logistic regression, after accounting for age ≥ 60 , receipt of montelukast was marginally associated with a lower risk of clinical deterioration (odds ratio 0.28, $p = 0.058$, CI = 0.072–1.04). Sensitivity analysis among those without asthma showed a trend toward fewer clinical deterioration events in the montelukast group than non-montelukast groups (11% vs. 33%, $p = 0.077$). Sensitivity analysis among those who did not receive azithromycin showed fewer clinical deterioration events in the montelukast group than non-montelukast groups (8% vs. 32%, $p = 0.030$). Sensitivity analysis among those who received steroids did not reveal a difference in clinical deterioration events ($p = 0.23$).

Discussion

In this retrospective study evaluating the efficacy of montelukast administration during hospitalization of patients diagnosed with COVID-19, clinical deterioration measured by changes in the COVID-19 Ordinal Scale was significantly lower in patients treated with montelukast compared to non-montelukast between Days 1 and 3. Oxygen escalation occurred in 32% of patients without montelukast versus 10% of patients taking montelukast. This was evident despite the montelukast group being of significantly older age ($p = 0.022$). Further, patients receiving montelukast had higher rates of baseline asthma and tended to have more cardiac comorbidities, potentially suggesting these patients had increased risk for clinical decompensation during COVID-19 infection. These findings suggest that montelukast may have clinical efficacy in reducing complications of COVID-19. With further evaluation, montelukast may be a potential therapy for COVID-19 infection.

We examined the effects of montelukast on laboratory values associated with COVID-19 illness and found no differences in inflammatory laboratory values including C-reactive protein, D-dimer, ferritin and LDH between montelukast vs non-montelukast patients. It is feasible that there were, in fact, no differences in the trends of laboratory values between patients treated with montelukast vs non-montelukast. However, given the lack of a method to grade these particular laboratory values, the differences in these values could not be accurately compared among patients and changes. We anticipate that the laboratory values of patients could be impacted by montelukast, but we were unable to derive an answer in this dataset. In addition, a limitation to this study was the lack of specific systemic or pulmonary cytokine measurements or serial SARS-CoV-2 viral loads that may better reflect the potential effect of montelukast on virally mediated pathways in SARS-CoV-2 infection. We found no difference in length of hospitalization between the two groups. However, we considered length of stay a subjective indicator of clinical outcome as there is no standardization between physician practices for decisions surrounding discharge time and planning.

Montelukast is a leukotriene receptor antagonist and binds with high affinity and selectivity to the CysLT₁ receptor. Eicosanoids including all cysteinyl leukotrienes (LTC₄, LTD₄, LTE₄) are products of arachidonic acid metabolism and are released from cells including mast cells and eosinophils¹². These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors which are found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells¹². CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis¹². In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. Furthermore, clinical findings indicate that montelukast can be used in the effective management of acute and post viral-induced wheezing¹³, and it can quickly improve respiratory function in acute asthmatic patients with an increased FEV₁ at 60 minutes post-montelukast administration and at all time points up to 120 minutes (n = 583)¹⁴. Another study documented data that asthmatic children treated with montelukast had higher lung function, decreased airway inflammation and lower symptom scores compared to the children not receiving montelukast¹⁵. While baseline asthma has not been found to be a risk factor for severe outcomes in COVID-19 [16], other comorbidities such as hypertension and diabetes have been correlated with worse prognosis [17]. In our study, 15 patients had a baseline diagnosis of asthma, 11 of whom received Montelukast during hospitalization.

The progression of COVID-19 infection to severe clinical complications owing to ARDS and a hyperinflammatory cytokine syndrome, or cytokine storm¹⁸. Secondary hemophagic lymphohistiocytosis (sHLH) is a hyperinflammatory syndrome leading to a fulminant and fatal hypercytokinemia with multiorgan failure in the setting of viral infections, and demonstrates unremitting fever, cytopenias, and hyperferritinemia; pulmonary involvement including ARDS occurs in 50% of patients¹⁸. Cytokine profiles resembling sHLH resemble COVID-19 disease severity, with increased IL-2, IL-7, GM-CSF, IFN-Gamma inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-alpha, and tumor necrosis factor alpha¹⁸. Viral hyperinflammation appeared to drive COVID-19 fatalities in Wuhan, China and predictors of mortality from COVID-19 cases in Wuhan included an elevated ferritin (1297.6 ng/mL in non-survivors vs 614 ng/mL in survivors, $p < 0.001$), and may suggest that fatalities are driven by viral hyperinflammation¹⁸. NF- κ B (nuclear factor kappa-light-chain-enhancer of activated B cells) can regulate immune responses, and its inhibition by MTK may attenuate the symptoms of COVID-19 by downregulating other inflammatory cytokines such as IL-6 and IL-8, mitigating the severity of infection and decreasing symptoms¹⁹.

We noted that treatment with montelukast had interesting results in subpopulations of interest. Sensitivity analysis among those without asthma showed a trend toward fewer events of clinical deterioration in the montelukast group compared to the no montelukast group. While montelukast is commonly used as an asthma maintenance therapy, our results suggest a benefit of montelukast independent from that found in its traditional use in asthma. Our sensitivity analyses did not find an independent effect of montelukast when administered along with these agents. Thus, co-administration may have blunted the anti-inflammatory effects of Montelukast in these populations.

Although the standard dosing of montelukast is 10 mg orally per day for allergic rhinitis, asthma, and prevention of exercise-induced asthma, montelukast has a favorable side effect profile with limited toxicities, indicating the potential to employ higher doses with relative safety and the possibility to better downregulate the viral pathophysiology of SARS-CoV-2 infection. Montelukast is safely administered without dose reductions regardless of hepatic or renal insufficiency, and common side effects of montelukast are similar to placebo and with the most common one being headache. Given that montelukast is a well-tolerated and a low-cost agent, information about dose responses/escalation in COVID-19 infection could be an important aspect to evaluate new dosing regimens, and could have impact on the duration and severity of symptoms of COVID-19 as well as which patients are most likely to benefit. These favorable characteristics of Montelukast are especially critical during the COVID-19 pandemic, as preventing clinical deterioration can save the use of depleted resources such as intensive care unit beds and mechanical ventilators.

Conclusions

Given the small sample size, retrospective nature of the study contributing to potential selection bias, the administration of montelukast as dictated by physician discretion, and limited data points in evaluation, the reduction in oxygen escalation observed in patients treated with montelukast versus without montelukast is promising and warrants further study with a larger sample size. In addition, the results of this study are intended to be hypothesis-generating and similar findings for the treatment of COVID-19 infection with montelukast would bolster the support for montelukast as a therapeutic agent for COVID-19. Rather than incorporation into practice without further study, we advocate for confirmatory clinical trials and additional retrospective data to support the incorporation of montelukast for the treatment of COVID-19. One such trial appears to be ongoing, such as NCT04389411, a phase 3 trial evaluating the use of montelukast compared to placebo for COVID-19 infection. Given the global toll of COVID-19 internationally on the burden of death and disease, new approaches such as treatment with montelukast, are urgently needed to decrease the impact of the disease on global healthcare systems, economies, and daily life.

Abbreviations

ARDS
Acute respiratory distress syndrome
CRP
C-reactive protein
LTRA
Leukotriene receptor antagonists
MTK
Montelukast
PCT

Procalcitonin test
Type-1 Alveolar Epithelial Cells (T1AECs)

Declarations

Ethics approval and consent to participate

This study was IRB-approved, at Robert Wood Johnson University Hospital, Rutgers University (Pro2020001307)

Consent for publication

Not applicable

Availability of data and materials

The dataset used and analyzed for this study are available from the corresponding author on request.

Competing Interests

No financial/nonfinancial disclosures except:

CH is the Chairman and CEO of Certa Dose, Inc. Neither CH or Certa Dose have any financial interests in the sale of Montelukast or any companies that manufacture Montelukast. JM, Research funding: BMS, Beyond Spring, Celldex, Biohaven; Advisory board: Astra Zeneca

MG is a Director of Scientific Affairs at Merck. Merck manufactures Singulair® which is available as generic montelukast. SKJ receives research funding and personal fees from Merck, unrelated to this work.

Funding

This study did not receive funding.

Authors' Contributions

All the authors listed meet authorship requirements. ARK, NYR, SK, and SKJ wrote the manuscript. Data collection was performed by ARK, CM, CM, and SKJ. NYR and SK performed the statistical analysis. Manuscript approval: all authors.

Acknowledgements

None.

Authors' information

Ahsan R. Khan (ark140@cinj.rutgers.edu)

Christian Misdary (cm1344@cinj.rutgers.edu)

Nikhil Yegya-Raman (nyegya@gmail.com)

Sinae Kim (sk1368@sph.rutgers.edu)

Navaneeth Narayanan (navan12@pharmacy.rutgers.edu)

Sheraz Siddiqui (siddiqsh@rwjms.rutgers.edu)

Padmini Salgame (salgampa@njms.rutgers.edu)

Jared Radbel (jr1106@rwjms.rutgers.edu)

Frank De Groote (degroote.vollekindt2@icloud.com)

Carl Michel (clm320@cinj.rutgers.edu)

Janice Mehnert (janice.mehnert@nyulangone.org)

Caleb Hernandez (caleb@certadose.com)

Thomas Braciale (tjb2r@virginia.edu)

Jyoti Malhotra (jm1940@cinj.rutgers.edu)

Michael A. Gentile (michael_gentile@merck.com)

Salma K. Jabbour (jabbousk@cinj.rutgers.edu)

References

1. Fidan C, Aydoğdu A. As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020;142:109828. doi:10.1016/j.mehy.2020.109828.
2. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J,.. . Zhong N. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. doi:10.1056/nejmoa2002032.

3. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020;130(5):2620–9. doi:10.1172/JCI137244.
4. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. *J Clin Invest.* 2020;130(5):2202–5. doi:10.1172/JCI137647.
5. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. *Eur Respir J.* 2020;55(4):2000607. doi:10.1183/13993003.00607-2020.
6. Cardani A, Boulton A, Kim TS, Braciale TJ. (2017). Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial Cells. *PLOS Pathogens*, 13(1). doi:10.1371/journal.ppat.1006140.
7. Cingi C, Muluk NB, Ipci K, Şahin E. (2015). Antileukotrienes in Upper Airway Inflammatory Diseases. *Current Allergy Asthma Reports*, 15(11). doi:10.1007/s11882-015-0564-7.
8. Mullol J, Callejas FB, Méndez-Arancibia E, et al. Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. *J Biol Regul Homeost Agents.* 2010 Oct-Dec;24(4):403–11.
9. Davino-Chiovatto JE, Oliveira-Junior MC, MacKenzieB, et al. Montelukast, Leukotriene Inhibitor, Reduces LPS-Induced Acute Lung Inflammation and Human Neutrophil Activation. *Arch Bronconeumol.* 2019 Nov;55(11):573–80. doi:10.1016/j.arbres.2019.05.003. Epub 2019 Jun 27. English, Spanish. PubMed PMID: 31257011.
10. CBS New York. (2020, April 22). Though Not FDA Approved, Off-Label Singulair Showing Promise As Coronavirus Treatment, Say Doctors. Retrieved July 11, 2020, from <https://newyork.cbslocal.com/2020/04/22/coronavirus-covid-19-singulair-montelukast/>.
11. World Health Organization. (2020, February 18). COVID-19 Therapeutic Trial Synopsis. Retrieved from: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf.
12. Choi J, Azmat CE. Leukotriene Receptor Antagonists. [Updated 2020 Feb 26]. In: StatPearls[Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: [https://www.ncbi.nlm.nih.gov/books/NBK554445/Kanchanateeraphong, S., Phongsamart, G., Dangsuwan, T., & Vangveeravong, M. \(2014\). Study Of Montelukast For The Treatment Of Acute and Post Viral-Induced Wheezing. Journal of Allergy and Clinical Immunology, 133\(2\). doi:10.1016/j.jaci.2013.12.681.](https://www.ncbi.nlm.nih.gov/books/NBK554445/Kanchanateeraphong, S., Phongsamart, G., Dangsuwan, T., & Vangveeravong, M. (2014). Study Of Montelukast For The Treatment Of Acute and Post Viral-Induced Wheezing. Journal of Allergy and Clinical Immunology, 133(2). doi:10.1016/j.jaci.2013.12.681.)
13. Camargo CA, Gurner DM, Smithline HA, Chapela R, Fabbri LM, Green SA, ... Reiss TF. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. *Journal of Allergy Clinical Immunology.* 2010;125(2):374–80. doi:10.1016/j.jaci.2009.11.015.
14. Straub DA. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. *Eur Respir J.* 2005;25(2):289–94. doi:10.1183/09031936.05.00031904.
15. Johnston SL. (2020). Asthma and COVID-19: Is asthma a risk factor for severe outcomes? *Allergy.* doi:10.1111/all.14348.

16. Guan W, Liang W, He J, Zhong N. Cardiovascular comorbidity and its impact on patients with COVID-19. *Eur Respir J*. 2020;55(6):2001227. doi:10.1183/13993003.01227-2020.
17. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033–4. doi:10.1016/S0140-6736(20)30628-0.
18. Maeba S, Ichiyama T, Ueno Y, Makata H, Matsubara T, Furukawa S. Effect of montelukast on nuclear factor κ B activation and proinflammatory molecules. *Ann Allergy Asthma Immunol*. 2005;94(6):670–4. doi:10.1016/s1081-1206(10)61326-9.